The same goes for the long delay in the study--if outside experts had been named ahead of time to make decisions about the data, there would be no debate over whether Merck and Schering did the right thing with regard to this trial.

FORBES: Vytorin's Missing Fail-Safes

Continued delay now leaves a long boom as the only time to control spending.

WSJ: Login/Register to set your edition